"The results of Regen's study will provide the safety profile data required for filing an IND application for the product with the FDA. Regen intends to file an IND application in the fourth quarter of 2012 and conduct Phase I/II trials during 2013 and 2014."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.